Efficacy of Short Pulsed 1064 nm Nd-YAG Laser Versus 10600 nm Fractional CO2 Laser in Treatment of Striae Alba
NCT ID: NCT04092881
Last Updated: 2020-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
31 participants
INTERVENTIONAL
2019-02-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All result in pathological changes comprising early dermal edema and perivascular lymphocytic infiltrate (manifest clinically as striae rubra) and end by epidermal thinning, flattening of dermal papillae, thinning of dermal collagen bundles and abundance of abnormally thinned and branched elastic fibers (manifest clinically as striae alba).
Various preventative and active treatment modalities for SD which were proven beneficial included: topical therapeutics like topical retinoids, energy based devices like fractional radiofrequency (FRF) and light therapy including both non-coherent light like intense pulsed light therapy and coherent laser devices like fractional ablative CO2 laser and non-ablative Nd-YAG laser. However obtaining a single effective treatment is still a challenge especially in absence of randomized control studies for some modalities and low level of evidence (LOE) for others.
Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in SD. The efficacy of fractional CO2 laser in treatment of striae alba was discussed in various studies. In a LOE 4 retrospective study involved 27 patients each received one session of fractional ablative CO2 laser (at 10 mJ using ultrapulsed deep FX mode with spot diameter 1-10 mm) ; (7.4%) of patients have shown (\>75 %) improvement, (51.9%) have shown (51 - 75%) improvement, (33.3%) have shown (26 - 50%) improvement and (7.4%) have shown (\<25%) improvement. Another comparative study between both fractional ablative CO2 laser and non-ablative Erbium-glass laser with LOE=2 conducted on 22 patients using three sessions with four weeks interval. Fractional CO2 laser parameters were set to (fluence = 40-50 mJ, 75-100 spots/Cm2 spot density and spot size = 8x8 mm in a static mode). Results have shown marked clinical improvement in 90.9% of patients from both modalities with no statistically significant difference between both. A third comparative study (LOE=2) between fractional CO2 laser, FRF and combination between both included 30 patients using (fluence=700-1000 mJ and 0.7 mm spot density) for the fractional CO2 laser. Clinical improvement was noticed in all three groups with best results for the combination group. This result was supported by histopathological evidence in the form of increased epidermal and collagen thickness in analysis of biopsies retrieved from two patients. A Fourth comparative study (LOE=2) between combination of fractional ablative CO2 laser and microneedle FRF versus only microneedle FRF conducted on six patients using five sessions with four weeks interval. Fractional CO2 was conducted using (fluence = 14-18J/Cm2 and ablation depth = 400-600 micrometers in ultrapulsed mode using two passes). A statistically significant better result was noticed in the combination group with overall greater reduction in mean surface area of SD pointing to an additive positive role for fractional CO2 laser. A fifth comparative study between fractional CO2 laser versus combination of topical glycolic acid and tretinoin (LOE=2) conducted on six patients through five sessions with two to four weeks interval. Fractional CO2 was set to (fluence = 14-18 J/Cm2 in ultrapulsed mode). Statistically significant better results were noticed in fractional CO2 laser group with reduction in mean surface area of SD.
Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) laser is another successful therapeutic modality and is characterized by its safe profile compared to other lasers. Long pulsed Nd-YAG laser results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections (14). El Saie and his colleagues compared the efficacy of two fluences (75 J/Cm2 and 100 J/Cm2) of Nd-YAG using (spot size = 5 mm, pulse duration = 15 ms and frequency = 1 Hz) in the treatment of SD (both striae alba and rubra patients). Improvement was noticed in both types of striae. However, patients with striae alba showed better improvement in the higher fluence group. Increased dermal collagen and elastin were supported by histopathological evidences for biopsies retrieved from six patients. Nevertheless, other studies pointed to higher effectiveness in cases of striae rubra than striae alba which suggests an additional role for Nd-YAG laser in targeting dermal vascular changes in SD.
There were no previous attempts for comparing fractional ablative CO2 laser and long pulsed non-ablative Nd-YAG laser for treatment of striae alba patients. In a recent systematic review, a LOE=2 comparative study was conducted between 2940nm Erbium - Yettrium Aluminum Garnet (Er-YAG) ablative laser and non-ablative 1064nm Nd-YAG laser for treatment of patient with striae alba. Each group received three sessions with four weeks interval. Parameters were set to (power= 3.2 J and spot size= 7mm in a short pulsed mode) for Er-YAG laser and (fluence= 50 J/Cm2, spot size= 50 ms and pulse duration = 50ms) for Nd-YAG laser. Both groups have shown poor results. Overall conclusion from systematic review was that ablative lasers as an option for treatment of SD were less well-tolerated by patients and results were more variable among studies than non-ablative lasers.
Clinical evaluation of patients shall be determined by Davey's modified score for the number and severity of the striae in the affected area, both before and after treatment to determine the degree of improvement or worsening.
Objective evaluation of the efficacy of different therapeutic modalities is highly important to determine the optimal management. High frequency skin ultrasound (HFSU) is a rapid and non-invasive tool for measurement of skin thickness and can be used for this purpose, It is an ultrasound-based apparatus that emits ultrasound waves through a transducer in high frequencies that vary according to the designated visualized structure or tissue. In skin, 18 MHz devices are used primarily for dermal component imaging and 50-100 MHz devices for epidermal component imaging. Using bimodal devices is a more advanced option for visualization of ultrastructures of the dermis like collagen, elastic fibers and dermal ground substance.
Statistical analysis shall be done after study completion to determine the significance of the outcome parameters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Detailed history taking including onset, course, duration of the disease and received medications.
* Serial digital photography before and after each session and three months after sessions.
* Clinical assessment to determine the severity of SD using modified Davey's visual score.
* Comparable sides of striae are randomly allocated to one of the treatment modalities in a randomized table technique.
* Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® Accelera mode) for one side and 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
* Assessment using high frequency skin ultrasound before session, before 4th session and 3 months after last session.
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Short pulsed Nd-YAG laser treatment side
Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.
Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections.
Laser
Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
Fractional ablative CO2 laser treatment side
Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.
CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.
Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae.
Laser
Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laser
Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
Laser
Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages between 14 years - 50 years.
* Both sexes.
* Skin types I-IV
* Bilateral striae.
Exclusion Criteria
* History of diseases associated with SD (cushing disease or Marfan syndrome).
* History of drugs associated with development of SD (topical or systemic glucocorticoids, Indinavir or protease inhibitors).
* History of conditions with abnormal dermal connective tissue structure (Ehler-Danlos syndrome, cutis laxa, pseudoxanthoma elasticum, elastolysis, elastomas, hyaline fibromatosis, keloidal tendencies, skin atrophy, poikiloderma or anetoderma).
* Current state of pregnancy in female patients.
* Relative contraindications to laser therapy (photosensitive dermatoses or burns).
* History of any therapeutic procedure for striae in the past 6 months before enrollment in the study.
* History of conditions associated with dermal edema or lymphedema.
14 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Manal Bosseila
Professor of dermatology - cairo university
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heba Abd El-Kader, MD
Role: STUDY_CHAIR
Lecturer of Dermatology, Cairo University
Manal A. Bosseila, MD
Role: PRINCIPAL_INVESTIGATOR
Professor of Dermatology, Cairo University
Khaled El Kaffas, MD
Role: STUDY_CHAIR
Associate Professor of Investigative Radiology, Department of Radiology, Cairo University
Omar M. El-Ghanam, MSc
Role: STUDY_DIRECTOR
Dermatology Specialist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cairo University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Mikes BA, Oakley AM, Patel BC. Striae Distensae. 2025 May 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK436005/
Ross NA, Ho D, Fisher J, Mamalis A, Heilman E, Saedi N, Jagdeo J. Striae Distensae: Preventative and Therapeutic Modalities to Improve Aesthetic Appearance. Dermatol Surg. 2017 May;43(5):635-648. doi: 10.1097/DSS.0000000000001079.
Omi T, Numano K. The Role of the CO2 Laser and Fractional CO2 Laser in Dermatology. Laser Ther. 2014 Mar 27;23(1):49-60. doi: 10.5978/islsm.14-RE-01.
Aldahan AS, Shah VV, Mlacker S, Samarkandy S, Alsaidan M, Nouri K. Laser and Light Treatments for Striae Distensae: A Comprehensive Review of the Literature. Am J Clin Dermatol. 2016 Jun;17(3):239-56. doi: 10.1007/s40257-016-0182-8.
Lee SE, Kim JH, Lee SJ, Lee JE, Kang JM, Kim YK, Bang D, Cho SB. Treatment of striae distensae using an ablative 10,600-nm carbon dioxide fractional laser: a retrospective review of 27 participants. Dermatol Surg. 2010 Nov;36(11):1683-90. doi: 10.1111/j.1524-4725.2010.01719.x. Epub 2010 Sep 14.
Yang YJ, Lee GY. Treatment of Striae Distensae with Nonablative Fractional Laser versus Ablative CO(2) Fractional Laser: A Randomized Controlled Trial. Ann Dermatol. 2011 Nov;23(4):481-9. doi: 10.5021/ad.2011.23.4.481. Epub 2011 Nov 3.
Ryu HW, Kim SA, Jung HR, Ryoo YW, Lee KS, Cho JW. Clinical improvement of striae distensae in Korean patients using a combination of fractionated microneedle radiofrequency and fractional carbon dioxide laser. Dermatol Surg. 2013 Oct;39(10):1452-8. doi: 10.1111/dsu.12268. Epub 2013 Jul 29.
Fatemi Naeini F, Behfar S, Abtahi-Naeini B, Keyvan S, Pourazizi M. Promising Option for Treatment of Striae Alba: Fractionated Microneedle Radiofrequency in Combination with Fractional Carbon Dioxide Laser. Dermatol Res Pract. 2016;2016:2896345. doi: 10.1155/2016/2896345. Epub 2016 Mar 16.
Naein FF, Soghrati M. Fractional CO2 laser as an effective modality in treatment of striae alba in skin types III and IV. J Res Med Sci. 2012 Oct;17(10):928-33.
Gianfaldoni S, Tchernev G, Wollina U, Fioranelli M, Roccia MG, Gianfaldoni R, Lotti T. An Overview of Laser in Dermatology: The Past, the Present and ... the Future (?). Open Access Maced J Med Sci. 2017 Jul 23;5(4):526-530. doi: 10.3889/oamjms.2017.130. eCollection 2017 Jul 25.
Gungor S, Sayilgan T, Gokdemir G, Ozcan D. Evaluation of an ablative and non-ablative laser procedure in the treatment of striae distensae. Indian J Dermatol Venereol Leprol. 2014 Sep-Oct;80(5):409-12. doi: 10.4103/0378-6323.140296.
Elsaie ML, Hussein MS, Tawfik AA, Emam HM, Badawi MA, Fawzy MM, Shokeir HA. Comparison of the effectiveness of two fluences using long-pulsed Nd:YAG laser in the treatment of striae distensae. Histological and morphometric evaluation. Lasers Med Sci. 2016 Dec;31(9):1845-1853. doi: 10.1007/s10103-016-2060-2. Epub 2016 Sep 5.
Hague A, Bayat A. Therapeutic targets in the management of striae distensae: A systematic review. J Am Acad Dermatol. 2017 Sep;77(3):559-568.e18. doi: 10.1016/j.jaad.2017.02.048. Epub 2017 May 24.
Bleve M, Capra P, Pavanetto F, Perugini P. Ultrasound and 3D Skin Imaging: Methods to Evaluate Efficacy of Striae Distensae Treatment. Dermatol Res Pract. 2012;2012:673706. doi: 10.1155/2012/673706. Epub 2011 Nov 22.
Davey CM. Factors associated with the occurrence of striae gravidarum. J Obstet Gynaecol Br Commonw. 1972 Dec;79(12):1113-4. doi: 10.1111/j.1471-0528.1972.tb11896.x. No abstract available.
Al-Himdani S, Ud-Din S, Gilmore S, Bayat A. Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment. Br J Dermatol. 2014 Mar;170(3):527-47. doi: 10.1111/bjd.12681.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Short Nd-YAG vs Fr.CO2 for SA
Identifier Type: -
Identifier Source: org_study_id